Physician profile
Swasha D Fields
NPI 1780003764
$2,625.07
in general payments reported to CMS, 2019-2025
20 companies · $706 in 2025
The $706 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2022: $51.38 · 2023: $597 · 2024: $1,062 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $627.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $523.92 | 2019-2025 | |
| Lilly USA, LLC | $340.81 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $269.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $205.88 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $101.19 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $71.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.37 | 2019-2024 | Jardiance |
| Dynavax Technologies Corporation | $65.26 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $59.72 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $59.48 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $46.91 | 2023-2024 | |
| Abbott Laboratories | $45.99 | 2023-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $37.71 | 2024 | Injectafer |
| Astellas Pharma US INC | $19.99 | 2025 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $19.39 | 2023 | |
| Horizon Therapeutics Plc | $17.46 | 2023 | Krystexxa |
| Nevro Corp. | $16.63 | 2024 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.20 | 2019 | |
| Boston Scientific Corporation | $15.09 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swasha Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.